1421 / 1835
Future Predictions for HL Salvage
•
More patients that had chemotherapy alone.
•
More patients that were exposed to Brentuximab early
•
RT will remain a major player in salvage
•
RT should be orchestrated optimally with old and new agents
•
Not all chemo refractory patients will require high dose therapy and ASCT
•
Standard allogeneic SCT will be replaced by other immunological
interventions